These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2651255)

  • 1. [Amino acids prevent hepatic encephalopathy. Ornithine-aspartate in hyperammonemia--results of a study].
    Hartung HD
    Fortschr Med; 1989 Mar; 107(8):56. PubMed ID: 2651255
    [No Abstract]   [Full Text] [Related]  

  • 2. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of relative deficiency].
    Sikorska H; Cianciara J; Wiercińska-Drapało A
    Pol Merkur Lekarski; 2010 Jun; 28(168):490-5. PubMed ID: 20642112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravenous administration of ornithine aspartate to patients with hepatic diseases].
    Schäfer W
    Munch Med Wochenschr; 1968 Oct; 110(43):2521-5. PubMed ID: 5755238
    [No Abstract]   [Full Text] [Related]  

  • 4. [Therapy of severe hyperammonemia].
    Leonhardt H; Bungert HJ
    Med Klin; 1972 Aug; 67(32):1052-6. PubMed ID: 5070916
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
    Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
    Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
    Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
    J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
    Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
    J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Parenteral feeding of patients with liver cirrhosis with hepatic encephalopathy].
    Ferenci P; Wewalka F
    Infusionsther Klin Ernahr; 1980 Apr; 7(2):72-8. PubMed ID: 6776052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current views on the therapy of hepatic coma].
    Ziegler K
    Z Gesamte Inn Med; 1970 Apr; 25(8):341-3. PubMed ID: 4331690
    [No Abstract]   [Full Text] [Related]  

  • 10. [Therapy of experimental and clinical hyperammonaemia with ornithine-alpha-ketoglutarate].
    Szám I; Szentner J; Hegedüs-Wein I; Vass A; Szilárd T
    Wien Med Wochenschr; 1974 May; 124(20):319-25. PubMed ID: 4829691
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment with aspartic acid in hepatic coma caused by hyperammonemia].
    Fodor O; Popescu S; Grigoraş D; Barbarino F
    Med Interna (Bucur); 1968 Jul; 20(7):781-5. PubMed ID: 5685308
    [No Abstract]   [Full Text] [Related]  

  • 12. [Research on the ammonium-binding action of aspartic acid in hepatic diseases].
    FODOR O; BORDA M; MANASIA M; SANTAY I
    Rev Int Hepatol; 1960; 10():895-908. PubMed ID: 13700435
    [No Abstract]   [Full Text] [Related]  

  • 13. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
    Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
    Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver].
    Ameri AA
    MMW Fortschr Med; 2010 Jun; 152(22):42-3. PubMed ID: 20590033
    [No Abstract]   [Full Text] [Related]  

  • 15. [On the therapy of liver diseases with ornithine aspartate].
    Melzer H; Weber D; Wotzka R
    Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.
    Kristiansen RG; Rose CF; Ytrebø LM
    Metab Brain Dis; 2016 Dec; 31(6):1269-1273. PubMed ID: 27339764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.
    Jalan R; Wright G; Davies NA; Hodges SJ
    Med Hypotheses; 2007; 69(5):1064-9. PubMed ID: 17467190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.
    Kristiansen RG
    Metab Brain Dis; 2016 Dec; 31(6):1357-1358. PubMed ID: 27651377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hepatic coma: use of certain Krebs' urea cycle intermediates (L-arginine, DL-ornithine).
    WOLFE SJ; FAST BB; STORMONT JM; DAVIDSON CS
    J Lab Clin Med; 1958 May; 51(5):672-89. PubMed ID: 13539483
    [No Abstract]   [Full Text] [Related]  

  • 20. [Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies].
    Krüger B; Held C; Kircheis G
    Z Arztl Fortbild (Jena); 1994 Sep; 88(9):673-9. PubMed ID: 7975752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.